{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,21]],"date-time":"2026-04-21T04:45:20Z","timestamp":1776746720987,"version":"3.51.2"},"reference-count":35,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,4,21]],"date-time":"2026-04-21T00:00:00Z","timestamp":1776729600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Endocrinol."],"abstract":"<jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>This study aimed to evaluate the independent discriminative performance of elevated Lipoprotein(a) [Lp(a)] in identifying prevalent cardiovascular disease (CVD), specifically in patients with Diabetes Mellitus (DM), and to determine the optimal cutoff values for identifying CVD in the DM population.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A stratified analysis was conducted across general, DM, and non-DM patient groups. Correlation analysis was employed to assess the association between elevated Lp(a) levels and metabolic factors in different age groups. Furthermore, binary regression was used to calculate combined risk scores. Receiver operating characteristic (ROC) curve analysis was utilized to determine the area under the curve (AUC) for the discriminative performance of Lp(a) alone, traditional parameters (excluding Lp(a)), and the combined model. This analysis identified the optimal cutoff values for each group.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Comparisons of Lp(a) variations showed that Lp(a)&amp;gt;300mg\/L was associated with an increased prevalence of CVDs in general and non-diabetic patients, while it was insignificant in patients with DM, unless the cutoff was set as low as 70mg\/L; Correlation analyses showed that, regardless of minor nuances between the general and DM groups, Lp(a) was significantly related to Low-density lipoprotein (LDL) and Apolipoprotein B (ApoB), but negatively related to Glycated Hemoglobin A1c (HbA1c), Triglycerides (TG), and free triiodothyronine (FT3); when stratified by age, no correlation was associated with Lp(a), but an association was found with CVD in the 65\u201375 age group, while Non-alcoholic fatty liver disease (NAFLD) prevalence was higher in the &amp;lt;65 age group across groups except for Lp(a)&amp;gt;70mg\/L in the DM group; correlational analyses revealed that Lp(a) was positively related with CVD in the &amp;lt;65 age group compared to the general group. Regression analyses revealed that HbA1c and age significantly contributed to increased CVD in DM and that Lp(a) was determined by FT3 and albumin (Alb) in DM; ROC curves demonstrated that the combination of Lp(a) with traditional parameters significantly enhanced the AUC for CVD in DM.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Elevated Lp(a) levels are significantly associated with CVD and demonstrate strong discriminative utility, particularly in patients with DM. These findings suggest that more stringent Lp(a) thresholds may be warranted in the clinical management of diabetic patients to better identify individuals at high risk for cardiovascular outcomes.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fendo.2026.1795181","type":"journal-article","created":{"date-parts":[[2026,4,21]],"date-time":"2026-04-21T04:21:32Z","timestamp":1776745292000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Enhanced independent discriminative performance of elevated lipoprotein(a) for cardiovascular outcomes in patients with diabetes: a comparative analysis of optimal cutoff values"],"prefix":"10.3389","volume":"17","author":[{"given":"Song","family":"Wen","sequence":"first","affiliation":[{"name":"Department of Endocrinology, Shanghai Pudong Hospital, Fudan University, Pudong Medical Center","place":["Shanghai, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yanju","family":"He","sequence":"additional","affiliation":[{"name":"Department of Endocrinology, Shanghai Pudong Hospital, Fudan University, Pudong Medical Center","place":["Shanghai, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiucai","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Endocrinology, Shanghai Pudong Hospital, Fudan University, Pudong Medical Center","place":["Shanghai, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhimin","family":"Xu","sequence":"additional","affiliation":[{"name":"Department of Endocrinology, Shanghai Pudong Hospital, Fudan University, Pudong Medical Center","place":["Shanghai, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dan","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, Shanghai Pudong Hospital, Fudan University, Pudong Medical Center","place":["Shanghai, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jiyu","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Surgery, Shanghai Pudong Hospital, Fudan University, Pudong Medical Center","place":["Shanghai, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ligang","family":"Zhou","sequence":"additional","affiliation":[{"name":"Department of Endocrinology, Shanghai Pudong Hospital, Fudan University, Pudong Medical Center","place":["Shanghai, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2026,4,21]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"102597","DOI":"10.1016\/j.arr.2024.102597","article-title":"Global trends and regional differences in mortality of cardiovascular disease and its impact on longevity, 1980-2021: Age-period-cohort analyses and life expectancy decomposition based on the Global Burden of Disease study 2021","volume":"103","author":"Xia","year":"2025","journal-title":"Ageing Res Rev"},{"key":"B2","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1186\/s12933-025-02961-9","article-title":"Insulin resistance-related indices, genetic risk, and the risk of cardiovascular disease in individuals with preclinical or clinical obesity: a large prospective cohort study in the UK biobank","volume":"24","author":"Hu","year":"2025","journal-title":"Cardiovasc Diabetol"},{"key":"B3","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1038\/s41392-023-01400-z","article-title":"Diabetic vascular diseases: molecular mechanisms and therapeutic strategies","volume":"8","author":"Li","year":"2023","journal-title":"Signal transduction targeted Ther"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1093\/eurjpc\/zwae038","article-title":"Impact of the 2021 European Society for Cardiology prevention guideline\u2019s stepwise approach for cardiovascular risk factor treatment in patients with established atherosclerotic cardiovascular disease","volume":"31","author":"Holtrop","year":"2024","journal-title":"Eur J Prev Cardiol"},{"key":"B5","doi-asserted-by":"publisher","first-page":"100651","DOI":"10.1016\/j.ajpc.2024.100651","article-title":"High lipoprotein(a): Actionable strategies for risk assessment and mitigation","volume":"18","author":"Reyes-Soffer","year":"2024","journal-title":"Am J Prev Cardiol"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1001\/jamacardio.2025.1603","article-title":"AHA PREVENT equations and lipoprotein(a) for cardiovascular disease risk: insights from MESA and the UK biobank","volume":"10","author":"Bhatia","year":"2025","journal-title":"JAMA Cardiol"},{"key":"B7","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1186\/s12933-025-02833-2","article-title":"Prognostic value of lipoprotein(a) for cardiovascular events after lower limb revascularization in diabetic patients with chronic limb-threatening ischemia","volume":"24","author":"Biscetti","year":"2025","journal-title":"Cardiovasc Diabetol"},{"key":"B8","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1186\/s12933-025-02722-8","article-title":"Atherogenic lipid parameters in people with normal glucose tolerance: implications from elevated 1-hour post-load plasma glucose","volume":"24","author":"Yang","year":"2025","journal-title":"Cardiovasc Diabetol"},{"key":"B9","doi-asserted-by":"publisher","first-page":"112940","DOI":"10.1016\/j.diabres.2025.112940","article-title":"Between Scylla and Charybdis - Enigmatic role of lipoprotein(a) in atherosclerotic cardiovascular disease and type 2 diabetes mellitus","volume":"229","author":"Li","year":"2025","journal-title":"Diabetes Res Clin Pract"},{"key":"B10","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1186\/s43556-024-00218-7","article-title":"The functions of apolipoproteins and lipoproteins in health and disease","volume":"5","author":"Ma","year":"2024","journal-title":"Mol BioMed"},{"key":"B11","doi-asserted-by":"publisher","first-page":"e033654","DOI":"10.1161\/JAHA.123.033654","article-title":"Genetics and pathophysiological mechanisms of lipoprotein(a)-associated cardiovascular risk","volume":"13","author":"Volgman","year":"2024","journal-title":"J Am Heart Assoc"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1161\/01.ATV.15.3.385","article-title":"Effect of glycation on the properties of lipoprotein(a)","volume":"15","author":"Makino","year":"1995","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.3390\/ijms262311427","article-title":"Diabetes mellitus and lipoprotein(a): A determinant interaction in micro- and macrovascular damage","volume":"26","author":"Polo-Barranco","year":"2025","journal-title":"Int J Mol Sci"},{"key":"B14","doi-asserted-by":"publisher","first-page":"123586","DOI":"10.1016\/j.ijbiomac.2023.123586","article-title":"Exploring the role of lipoprotein(a) in cardiovascular diseases and diabetes in Chinese population","volume":"233","author":"Hussain","year":"2023","journal-title":"Int J Biol macromolecules"},{"key":"B15","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1016\/S0021-9150(99)00381-0","article-title":"Glycation amplifies lipoprotein(a)-induced alterations in the generation of fibrinolytic regulators from human vascular endothelial cells","volume":"150","author":"Zhang","year":"2000","journal-title":"Atherosclerosis"},{"key":"B16","doi-asserted-by":"publisher","first-page":"117545","DOI":"10.1016\/j.atherosclerosis.2024.117545","article-title":"Modification of lipoprotein metabolism and function driving atherogenesis in diabetes","volume":"394","author":"Luciani","year":"2024","journal-title":"Atherosclerosis"},{"key":"B17","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1007\/s11154-008-9078-0","article-title":"Proteoglycan mediated lipoprotein retention: a mechanism of diabetic atherosclerosis","volume":"9","author":"Tannock","year":"2008","journal-title":"Rev Endocr Metab Disord"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1007\/s11892-024-01543-5","article-title":"Exploring the interplay between diabetes and lp(a): implications for cardiovascular risk","volume":"24","author":"Pablo","year":"2024","journal-title":"Curr Diabetes Rep"},{"key":"B19","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/j.ijcard.2010.02.021","article-title":"Lipoprotein(a) is strongly associated with coronary artery calcification in type-2 diabetic women","volume":"150","author":"Qasim","year":"2011","journal-title":"Int J Cardiol"},{"key":"B20","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1016\/j.pcad.2022.01.002","article-title":"Global think tank on the clinical considerations and management of lipoprotein(a): The top questions and answers regarding what clinicians need to know","volume":"73","author":"Virani","year":"2022","journal-title":"Prog Cardiovasc Dis"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1373\/clinchem.2010.146779","article-title":"Lipoprotein(a) and risk of type 2 diabetes","volume":"56","author":"Mora","year":"2010","journal-title":"Clin Chem"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2019.10.019","article-title":"Lipoprotein(a) concentration and risks of cardiovascular disease and diabetes","volume":"74","author":"Gudbjartsson","year":"2019","journal-title":"J Am Coll Cardiol"},{"key":"B23","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1186\/s12944-021-01504-x","article-title":"High lipoprotein(a) concentrations are associated with lower type 2 diabetes risk in the Chinese Han population: a large retrospective cohort study","volume":"20","author":"Fu","year":"2021","journal-title":"Lipids Health Dis"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1016\/j.metabol.2014.08.007","article-title":"Relationships of plasma lipoprotein(a) levels with insulin resistance in hypertensive patients","volume":"63","author":"Marzano","year":"2014","journal-title":"Metabolism"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1007\/s001250051110","article-title":"Insulin suppresses apolipoprotein(a) synthesis by primary cultures of cynomolgus monkey hepatocytes","volume":"42","author":"Neele","year":"1999","journal-title":"Diabetologia"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehz310","article-title":"Statin therapy increases lipoprotein(a) levels","volume":"41","author":"Tsimikas","year":"2020","journal-title":"Eur Heart J"},{"key":"B27","doi-asserted-by":"publisher","first-page":"100885","DOI":"10.1016\/j.ajpc.2024.100885","article-title":"Lipoprotein(a) throughout life in women","volume":"20","author":"Corral","year":"2024","journal-title":"Am J Prev Cardiol"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-8587(18)30048-2","article-title":"Mean HbA(1c), HbA(1c) variability, and mortality in people with diabetes aged 70 years and older: a retrospective cohort study","volume":"6","author":"Forbes","year":"2018","journal-title":"Lancet Diabetes Endocrinol"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehx033","article-title":"Lipoprotein(a): the revenant","volume":"38","author":"Gencer","year":"2017","journal-title":"Eur Heart J"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1016\/0021-9150(95)05600-2","article-title":"Non-enzymatic glycation of lipoprotein(a)","volume":"118","author":"Doucet","year":"1995","journal-title":"Vitro vivo Atheroscl"},{"key":"B31","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1016\/S0021-9150(96)06033-9","article-title":"Comparison of antioxidant activity in lipoprotein fractions from insulin-dependent diabetics and healthy controls","volume":"129","author":"Maxwell","year":"1997","journal-title":"Atherosclerosis"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1007\/BF00401055","article-title":"Coagulation activation in diabetes mellitus: the role of hyperglycaemia and therapeutic prospects","volume":"36","author":"Ceriello","year":"1993","journal-title":"Diabetologia"},{"key":"B33","doi-asserted-by":"publisher","first-page":"100945","DOI":"10.1016\/j.ajpc.2025.100945","article-title":"Rethinking cardiovascular risk: The emerging role of lipoprotein(a) screening","volume":"21","author":"Clair","year":"2025","journal-title":"Am J Prev Cardiol"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(24)01308-4","article-title":"Lipoprotein(a) and cardiovascular disease","volume":"404","author":"Nordestgaard","year":"2024","journal-title":"Lancet (London England)"},{"key":"B35","doi-asserted-by":"publisher","first-page":"264","DOI":"10.1186\/s12933-025-02816-3","article-title":"Efficacy and safety of Tafolecimab in Chinese patients with type 2 diabetes and hypercholesterolemia: a post-hoc analysis of pooled data from three phase 3 trials","volume":"24","author":"Qi","year":"2025","journal-title":"Cardiovasc Diabetol"}],"container-title":["Frontiers in Endocrinology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2026.1795181\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,21]],"date-time":"2026-04-21T04:21:35Z","timestamp":1776745295000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2026.1795181\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,21]]},"references-count":35,"alternative-id":["10.3389\/fendo.2026.1795181"],"URL":"https:\/\/doi.org\/10.3389\/fendo.2026.1795181","relation":{},"ISSN":["1664-2392"],"issn-type":[{"value":"1664-2392","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,21]]},"article-number":"1795181"}}